Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea

Background: Empagliflozin has been shown to reduce cardiovascular morbidity and mortality in patients with type 2 diabetes. Various research on its efficacy in patients with chronic kidney disease (CKD) have been actively conducted. So far, few studies have investigated the safety of these adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Ha Young, Kim, In-Wha, Oh, Jung Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610004/
https://www.ncbi.nlm.nih.gov/pubmed/37896154
http://dx.doi.org/10.3390/pharmaceutics15102394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610004/
https://www.ncbi.nlm.nih.gov/pubmed/37896154
http://dx.doi.org/10.3390/pharmaceutics15102394

Ejemplares similares